Cargando…

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer

BACKGROUND: MammaPrint (MMP) helps clinicians identify the ideal time for adjuvant treatment for patients with early HR+/HER2− breast cancer. We aimed to validate a nomogram designed to predict probability of low risk of MMP results and to evaluate the difference in survival outcome between two grou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Young Sol, Kim, Hwa Jung, Kim, Jisun, Chung, Il Yong, Ko, Beom Seok, Kim, Hee Jeong, Lee, Jong Won, Son, Byung Ho, Ahn, Sei-Hyun, Lee, Sae Byul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789221/ https://www.ncbi.nlm.nih.gov/pubmed/36564593 http://dx.doi.org/10.1007/s12672-022-00604-z

Ejemplares similares

A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Lee, Young Joo, et al.
Publicado: (2021)

Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016)

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020)

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
por: Espinel, C. Francisco, et al.
Publicado: (2012)

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
por: Haan, Josien C., et al.
Publicado: (2021)

Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
por: Fatima, Areej, et al.
Publicado: (2017)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Myburgh, Ettienne J., et al.
Publicado: (2021)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019)

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
por: Pan, Bo, et al.
Publicado: (2023)

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
por: Slembrouck, Laurence, et al.
Publicado: (2019)

RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Mansani, Fabio Postiglione, et al.
Publicado: (2022)

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing
por: Bai, Qianming, et al.
Publicado: (2023)

A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction
por: Yao, Kevin, et al.
Publicado: (2022)

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer
por: Lee, Sae Byul, et al.
Publicado: (2019)

Magnetic resonance imaging based 3-dimensional printed breast surgical guide for breast-conserving surgery in ductal carcinoma in situ: a clinical trial
por: Wu, Zhen-Yu, et al.
Publicado: (2020)

Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
por: Lee, Sae Byul, et al.
Publicado: (2021)

Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study
por: Kim, Hakyoung, et al.
Publicado: (2022)

MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy
por: Ko, Beom Seok, et al.
Publicado: (2019)

A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2018)

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Blumencranz, Peter, et al.
Publicado: (2023)

Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence
por: Baek, Soo Yeon, et al.
Publicado: (2022)

Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2021)

Non-sentinel node metastasis prediction during surgery in breast cancer patients with one to three positive sentinel node(s) following neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2023)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study
por: Lee, Sae Byul, et al.
Publicado: (2018)

Survival outcomes of breast cancer patients with recurrence after surgery according to period and subtype
por: Lee, Young-jin, et al.
Publicado: (2023)

Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution’s experience
por: Alqudaihi, Heba Mohammad Abdulla, et al.
Publicado: (2022)

Salivary Duct Cancer Metastasis Mimicking Primary Breast Cancer: A Case Report and Review
por: Alzuhair, Aisha M., et al.
Publicado: (2019)

Factors in Parenting Stress in Young Patients With Breast Cancer and Implications for Children’s Emotional Development: The PSYCHE Study
por: Shin, Yungil, et al.
Publicado: (2023)

Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer
por: Lee, Young-Won, et al.
Publicado: (2023)

Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment
por: Lee, Han Shin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ql576ehqkt0dhti5qcactnq514